Protagonist Therapeutics (PTGX) to Release Earnings on Thursday

Protagonist Therapeutics (NASDAQ:PTGX) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Protagonist Therapeutics to post earnings of ($0.59) per share and revenue of $5.4070 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 7, 2025 at 3:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). The company had revenue of $5.55 million during the quarter, compared to the consensus estimate of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. On average, analysts expect Protagonist Therapeutics to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Protagonist Therapeutics Stock Down 2.3%

PTGX stock opened at $76.69 on Thursday. Protagonist Therapeutics has a twelve month low of $33.31 and a twelve month high of $93.25. The business has a 50 day moving average price of $65.74 and a two-hundred day moving average price of $55.99. The company has a market cap of $4.77 billion, a price-to-earnings ratio of 109.56 and a beta of 2.20.

Insider Activity

In other news, Director William D. Waddill sold 12,000 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $81.62, for a total value of $979,440.00. Following the completion of the sale, the director owned 5,130 shares of the company’s stock, valued at approximately $418,710.60. The trade was a 70.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 20,000 shares of company stock valued at $1,473,440 over the last three months. Insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Several institutional investors have recently made changes to their positions in PTGX. Royal Bank of Canada boosted its stake in shares of Protagonist Therapeutics by 30.6% in the first quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock valued at $482,000 after buying an additional 2,334 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after acquiring an additional 348 shares during the period. Millennium Management LLC lifted its position in shares of Protagonist Therapeutics by 283.6% during the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock valued at $6,493,000 after acquiring an additional 99,269 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at $987,000. Finally, Guggenheim Capital LLC lifted its position in shares of Protagonist Therapeutics by 1.6% during the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after acquiring an additional 303 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. BMO Capital Markets reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Johnson Rice set a $112.00 target price on Protagonist Therapeutics in a research note on Monday, October 13th. Leerink Partnrs upgraded Protagonist Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, October 8th. Finally, Truist Financial lifted their price objective on shares of Protagonist Therapeutics from $76.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.08.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.